Carlyle May Sell 10% Stake in India's Piramal Pharma for $315M

Key Takeaways

Sector: Biotechnology & Life Sciences.
Geography: India.

Analysis

Carlyle Group is reportedly preparing to divest up to a 10% stake in Piramal Pharma, the Mumbai-based pharmaceutical firm, in a deal that could generate between INR 26–27 billion (approximately $305–$315 million USD), according to sources cited by Moneycontrol. The transaction is expected to be conducted via block trades on Indian stock exchanges.

Carlyle currently owns an 18% stake in Piramal Pharma through its affiliate CA Alchemy Investments, having originally acquired a 20% stake in 2020 for around $490 million. At the time, the transaction marked one of the most notable private equity investments in India’s pharma space, aligning Carlyle with a growing leader in complex generics, injectables, and active pharmaceutical ingredients (APIs).

The proposed partial exit underscores a maturing phase for private equity in India’s healthcare and life sciences sector, which continues to attract robust global interest. Rising demand for affordable and quality healthcare, coupled with strong export potential and regulatory alignment with global markets, has made Indian pharmaceutical assets highly attractive to international investors.

Carlyle’s move comes at a time when Piramal Pharma’s shares have seen upward momentum amid resilient earnings and sustained domestic and international growth. Analysts note that such stake sales are often timed to capitalize on market liquidity and may signal a portfolio rebalancing strategy rather than a negative view of the company’s fundamentals.

Neither Carlyle nor Piramal Pharma has issued public statements on the reported transaction. However, sources suggest the deal could be executed in the near term, depending on market conditions and institutional investor demand.

This development also reflects a broader pattern among private equity firms globally, where investors are selectively monetizing long-held positions to redeploy capital into new opportunities, particularly in emerging markets.